prifemilast

Asset

Inhibits PDE4, increasing intracellular cyclic AMP and suppressing inflammatory signaling.

Stage
Phase 3
Modality
Small molecule
Target
Inflammation
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains5
  • Owner and partners2
  • Evidence for its targets5
  • Competitors7
  • Aging relevance1
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets